The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC): Real-world data in Germany (QS Ovar of the AGO Study Group).
 
Sven Mahner
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Janssen-Cilag; Jenapharm; Medac; Novartis/Pfizer; PharmaMar; Roche/Genentech; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Immunogen; Janssen-Cilag; Medac; Merck Sharp & Dohme; Roche; Sensor-Kinesis Corp.; Tesaro
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Janssen-Cilag; Medac; PharmaMar; Roche; Tesaro
 
Philipp Harter
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Merck; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Roche (Inst)
 
Andreas Du Bois
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; Ingress Health; Mersana; Roche/Genentech; Zodiac Pharma
 
Felix Hilpert
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD
 
Markus Kerkmann
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pharmacosmos (Inst); Roche Pharma AG (Inst); Takeda (Inst)
 
Jalid Sehouli
Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro
 
Nikolaus de Gregorio
Consulting or Advisory Role - AstraZeneca/Merck; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Myriad Genetic Laboratories; Roche
 
Lars Ch. Hanker
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Pfizer; Roche Pharma AG
 
Florian Heitz
Honoraria - AstraZeneca; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Novocure; PharmaMar; Roche
Research Funding - Amedes (Inst); AstraZeneca (Inst)
 
Frederik Marmé
Honoraria - AGENDIA; Amgen; AstraZeneca; Celgene; Clovis Oncology; Clovis Oncology; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Lilly; MSD Oncology; Myriad Genetics; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche/Genentech; Seagen; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); CureVac; Eisai; Genomic Health; Gilead Sciences; GlaxoSmithKline; Immunomedics (Inst); Pfizer; Roche (Inst); Tesaro; Vaccibody (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Tesaro (Inst); Vaccibody (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Linn Lena Woelber
Honoraria - GlaxoSmithKline; Medac; MSD; Pfizer; promedicis; Roche; Seagen; Tesaro; Teva
Consulting or Advisory Role - Eisai Europe; Genmab; Roche; Seagen; Tesaro
Research Funding - Medac (Inst); Roche Molecular Diagnostics (Inst)
 
Laura Holtmann
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pharmacosmos (Inst); Roche (Inst); Takeda (Inst)
 
Gabriele Elser
No Relationships to Disclose
 
Jacobus Pfisterer
Honoraria - Amgen; AstraZeneca; Axiom Healthcare Strategies; Bionest Partner; Chugai Pharma; Clovis Oncology; Decision Resources; GlaxoSmithKline; iMed Institut; Juniper Pharmaceuticals; Lilly; Medupdate; MSD Oncology; Prosapient; Roche Pharma AG; SAI MedPartners; SAI MedPartners; Simon-Kucher and Partners; Teva; Vox.Bio
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; MSD Oncology; Roche Pharma AG; Tesaro
Research Funding - Roche Pharma AG (Inst); Roche Pharma AG (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Roche Pharma AG